South Korea Vaccines Market Insight
Published: 24 June 2026 | Report Format: Electronic (PDF) | Author: Komal and Radhika
The South Korea vaccines market is expected to witness robust growth at a CAGR of 6.85% owing to rising aging population, preventive healthcare shift, government support.
South Korea Vaccines Market Insights Forecasts to 2035
- The South Korea Vaccines Market Size Was Estimated at USD 845.2 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.85% from 2025 to 2035
- The South Korea Vaccines Market Size is Expected to Reach around USD 1,639.4 Million by 2035
Notable Insights for the South Korea Vaccines Market
- The product-based segmentation indicates that the Recombinant Vaccines segment holds a commanding position with almost 56% market share in South Korea in 2025 due to premium manufacturing pipelines.
- The application-based segmentation shows that the Pediatric Human Vaccines segment dominates with a market share of almost 61% in the South Korean market in 2025 following national immunization schemes.
- The regional revenue for SK Bioscience in fiscal year 2025 was estimated at about $420 million, driven by rising demand for localized cell-culture flu shots and advanced contract manufacturing.
- As per expectations, rising emission-compliant processing trends and automated factory tracking platforms along with increasing vial production infrastructure will drive market expansion where specialized facilities improve output up to 46%.
Download the eBook (ToC)
Research Methodologies Used to Analyze the South Korea Vaccines Market
The South Korean market for vaccines will be assessed using a combination of both primary (interviews) and secondary (review of published materials) research methods to ensure that the information gathered is as precise as possible, as well as providing details on projected future performance of the market itself. Primary research will occur through interviews with: biotechnology manufacturers; clinical research directors; regulatory experts; hospital purchasing professionals; and healthcare policy administrators; and through these interviews consumption patterns, pricing dynamics, and competitor activity will be reviewed. Secondary research will consist of the analysis of reports published by companies and governments, in addition to medical toxicology journals; international trade databases; and regulatory agencies associated with The Ministry of Food & Drug Safety and the healthcare industry. All market estimates; trend analyses; and forecasting methodologies will be used to estimate the size of this market; opportunities for future growth; changes to technology in relation to vaccines; and potential for strategic investment in this sector.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Vaccines Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Vaccines Market
- SK Bioscience Co., Ltd.
- GC Biopharma (Green Cross Corporation)
- LG Chem Ltd. (Life Sciences Division)
- HK inno.N Corporation
- Boryung Co., Ltd.
- EuBiologics Co., Ltd.
- Celltrion Inc.
- Samsung Biologics (mRNA Business Division)
- Genoxine Inc.
- Cha Biotech Co., Ltd.
Recent Developments:
- In February 2026, SK Bioscience Co., Ltd. expanded its eco-friendly vaccine production portfolio with advanced cell-culture manufacturing infrastructure designed for rapid viral response and premium pediatric global compliance.
- In September 2025, GC Biopharma introduced its next-generation high-potency quadrivalent influenza vaccines with tailored safety profiles to support distribution through modern domestic distribution systems and through national immunization programs.
Market Segmentation:
South Korea Vaccines Market, By Technology
- Recombinant & Subunit Vaccines
- mRNA & Nucleic Acid Formulations
- Inactivated & Conjugate Options
- Live Attenuated Viral Strains
- Viral Vector Platforms
South Korea Vaccines Market, By Indication
- Pneumococcal Infections
- Influenza & Seasonal Flu
- Human Papillomavirus (HPV)
- Hepatitis B & Viral Diseases
- Other Infectious Disease Vectors
South Korea Vaccines Market, By Application
- Pediatric Human Immunization
- Adult & Geriatric Prophylaxis
- Travel & Military Health Sectors
- Commercial Clinical Outpatient Care
- Emergency Government Stockpiles
Expert Views:
The growth of vaccine markets in South Korea will be facilitated by increased use of modern sustainable formulations, rising commercial fleet developments, and higher demand for specialized high-performance structural lubrication tools. The use of advanced blending methods, automated fabrication lines, and digital quality monitoring technologies will contribute to improved procedural efficiency and enhanced demand across multiple critical transportation and transport application sectors
Author: Komal and Radhika By Decisions Advisors and Consulting